Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Pediatrix Medical (MD) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Pediatrix Medical (MD) over the last 17 years, with Q1 2025 value amounting to $361.0 million.

  • Pediatrix Medical's Other Operating Expenses fell 1205.32% to $361.0 million in Q1 2025 from the same period last year, while for Sep 2025 it was $362.3 million, marking a year-over-year decrease of 933.25%. This contributed to the annual value of -$9.7 million for FY2024, which is N/A changed from last year.
  • Pediatrix Medical's Other Operating Expenses amounted to $361.0 million in Q1 2025, which was down 1205.32% from $1.2 million recorded in Q4 2024.
  • In the past 5 years, Pediatrix Medical's Other Operating Expenses registered a high of $410.5 million during Q1 2024, and its lowest value of -$10.9 million during Q2 2024.
  • Moreover, its 5-year median value for Other Operating Expenses was $365.8 million (2021), whereas its average is $294.8 million.
  • In the last 5 years, Pediatrix Medical's Other Operating Expenses surged by 1635.21% in 2021 and then plummeted by 1205.32% in 2025.
  • Quarter analysis of 5 years shows Pediatrix Medical's Other Operating Expenses stood at $368.5 million in 2021, then rose by 10.5% to $407.2 million in 2022, then fell by 1.29% to $401.9 million in 2023, then plummeted by 99.69% to $1.2 million in 2024, then surged by 29182.16% to $361.0 million in 2025.
  • Its Other Operating Expenses stands at $361.0 million for Q1 2025, versus $1.2 million for Q4 2024 and -$59000.0 for Q3 2024.